Embryo Biopsy

Embryo biopsy is a laboratory procedure used during in vitro fertilization (IVF) to remove a small number of cells from an embryo so those cells can be genetically tested before embryo transfer. It matters because it can help identify embryos that may have certain chromosome abnormalities or specific inherited genetic conditions, which may affect implantation, miscarriage risk, or the chance of passing on a known disorder. For men and couples navigating fertility treatment, embryo biopsy is not a fertility treatment by itself, but a tool that may guide embryo selection in carefully chosen situations.

At a glance
What is embryo biopsy?
Why embryo biopsy is done
What embryo biopsy means in men's fertility
How the process works
Types of genetic testing after embryo biopsy
Day 3 vs day 5 embryo biopsy
What's normal vs what's not?
Benefits, limitations, and risks
Male factor infertility and sperm quality
Who might consider embryo biopsy?
When to talk to a fertility specialist
Questions to ask your doctor
Related tests and terms
Frequently asked questions
References

At a glance

Embryo biopsy removes a few cells from an IVF embryo for genetic testing.
It is most often performed at the blastocyst stage, usually on day 5, 6, or 7.
The biopsy itself does not treat infertility; it helps provide genetic information about an embryo.
Testing may be used for chromosome screening or for specific inherited diseases when a known genetic risk exists.
Results are helpful, but they are not perfect. False positives, false negatives, and mosaic results can occur.
Embryo biopsy is especially relevant for some couples with recurrent pregnancy loss, advanced maternal age, repeated IVF failure, or known genetic conditions.
Male factor infertility can contribute to embryo quality and chromosomal problems, but it does not automatically mean embryo biopsy is needed.
Decisions about biopsy and preimplantation genetic testing should be individualized with a reproductive endocrinologist and genetics team.

What is embryo biopsy?

Embryo biopsy is the removal of one or more cells from an embryo created through IVF so those cells can be analyzed in a genetics lab. The goal is usually to perform preimplantation genetic testing, often called PGT, before the embryo is transferred to the uterus.

Today, embryo biopsy is most commonly performed at the blastocyst stage, when the embryo has developed into a structure with two main cell groups: the inner cell mass, which becomes the fetus, and the trophectoderm, which becomes much of the placenta. In modern IVF practice, the biopsy typically samples a few trophectoderm cells rather than cells from the inner cell mass. This approach is generally preferred because it avoids directly sampling the part that becomes the fetus and has become standard in many clinics and laboratories, as described by the American Society for Reproductive Medicine and ESHRE.

You may also hear embryo biopsy described alongside terms such as:

Preimplantation genetic testing (PGT)
PGT-A for aneuploidy screening
PGT-M for monogenic or single-gene disorders
PGT-SR for structural chromosome rearrangements
Blastocyst biopsy
Trophectoderm biopsy

Although people sometimes use these terms interchangeably, embryo biopsy is the sampling step, while PGT is the genetic analysis performed on those sampled cells.

Why embryo biopsy is done

Embryo biopsy is done to gather genetic information that may help clinicians and patients decide which embryo to transfer, freeze, or in some cases not use. Depending on the clinical situation, the goals may include:

Identifying embryos with the expected number of chromosomes
Reducing the chance of transferring an embryo affected by a specific inherited disease
Improving embryo selection when there is a known genetic risk
Potentially lowering the chance of miscarriage in selected patients when aneuploid embryos are avoided
Helping guide IVF decisions after repeated failed cycles or recurrent pregnancy loss

It is important to keep expectations realistic. Embryo biopsy and PGT may improve decision-making, but they do not guarantee pregnancy, a live birth, or a healthy baby. The ASRM committee opinion on PGT-A emphasizes that benefits vary by patient group and that routine universal use is not supported in every IVF case.

What embryo biopsy means in men's fertility

For men, embryo biopsy usually enters the conversation when male factor infertility affects fertilization, embryo development, or the risk of genetic problems in embryos. This does not mean sperm is always the cause, but it does mean sperm health is part of the bigger reproductive picture.

Male fertility factors that may be relevant include:

Low sperm count or severe oligospermia
Poor sperm motility
Abnormal sperm morphology
High sperm DNA fragmentation
Y chromosome microdeletions or other genetic findings
Balanced chromosomal rearrangements, such as a translocation
Advanced paternal age, which may be associated with some genetic risks, although the relationship is complex

When a man carries a known inherited mutation or a structural chromosome rearrangement, embryo biopsy may be used with PGT-M or PGT-SR to reduce the chance of passing that issue to a child. If the issue is non-genetic male factor infertility, embryo biopsy is less straightforward. It may provide information about embryo chromosomes, but it does not correct poor sperm quality or fix the underlying male fertility problem.

Research suggests sperm quality, including DNA damage, can influence embryo development and reproductive outcomes, but embryo biopsy is not a substitute for a full male fertility evaluation. A semen analysis, hormonal testing, medical history, and sometimes genetic workup are still essential. The NICHD overview of male infertility and the AUA/ASRM male infertility guideline outline how male factors should be evaluated.

How the process works

Embryo biopsy happens within the IVF process and usually follows egg retrieval and fertilization. In most modern cycles, embryos are cultured to the blastocyst stage before biopsy.

Step-by-step process

Ovarian stimulation and egg retrieval: Eggs are collected from the ovaries.
Fertilization: Eggs are fertilized with sperm, often using intracytoplasmic sperm injection (ICSI), especially when PGT is planned, to reduce contamination from extra sperm.
Embryo culture: Embryos develop in the lab for several days.
Biopsy: A few trophectoderm cells are removed from a blastocyst using micromanipulation techniques.
Freezing: The biopsied embryo is commonly frozen while test results are pending.
Genetic analysis: The sampled cells are tested in a specialized genetics laboratory.
Embryo transfer planning: Based on results and the full clinical picture, one embryo may later be thawed and transferred.

The biopsy itself is performed by highly trained embryologists. A tiny opening may be created in the outer shell of the embryo, called the zona pellucida, often using a laser. The selected cells are gently removed and sent for analysis. According to the UK Human Fertilisation and Embryology Authority, PGT is a highly specialized process used in specific IVF scenarios rather than standard testing for everyone.

Does the biopsy hurt the embryo?

This is one of the most common concerns. The short answer is that embryo biopsy is designed to minimize harm, and many clinics perform it routinely at the blastocyst stage. Still, it is not entirely risk-free. Some embryos may not survive biopsy or subsequent freezing and thawing, and some may be affected in ways that are difficult to measure. That is one reason careful patient selection and experienced lab technique matter.

Types of genetic testing after embryo biopsy

Once embryo cells are removed, they can be tested in different ways depending on the medical reason for testing.

PGT-A

PGT-A stands for preimplantation genetic testing for aneuploidy. It looks for embryos with extra or missing chromosomes. Humans typically have 46 chromosomes arranged in 23 pairs. An embryo with an abnormal chromosome number is called aneuploid. Some aneuploid embryos fail to implant, some lead to miscarriage, and some can cause genetic conditions such as trisomy 21.

PGT-A does not test every possible genetic disease. It mainly examines chromosome number.

PGT-M

PGT-M is used when one or both genetic parents carry a known pathogenic variant associated with a single-gene condition, such as cystic fibrosis or sickle cell disease. The purpose is to identify embryos that are affected or that carry the mutation, depending on the inheritance pattern and the couple's goals.

PGT-SR

PGT-SR is used for people with structural chromosome rearrangements, such as balanced translocations or inversions. A person with a balanced rearrangement may be healthy but still produce embryos with unbalanced chromosome content, which can affect pregnancy outcomes.

Comparison table

Type	What it looks for	Who may consider it	Important limitation
PGT-A	Extra or missing chromosomes	Selected IVF patients, often depending on age, history, and clinic approach	Does not guarantee implantation or live birth
PGT-M	Specific inherited single-gene disorder	Known carriers or families with a diagnosed genetic condition	Requires prior identification of the mutation and custom test setup
PGT-SR	Unbalanced embryos from structural rearrangements	Individuals with translocations or inversions	May not detect every possible embryo abnormality outside the targeted issue

Day 3 vs day 5 embryo biopsy

Older IVF protocols sometimes used cleavage-stage biopsy on day 3, when the embryo had around 6 to 8 cells and one cell was removed. Modern practice more often favors blastocyst-stage biopsy on day 5 or later.

Feature	Day 3 biopsy	Day 5 or 6 biopsy
Stage	Cleavage-stage embryo	Blastocyst
Cells removed	Usually 1 cell	Usually several trophectoderm cells
Common use today	Less common	More common
Sampling target	Embryo cell at early stage	Placenta-forming cell layer, not inner cell mass
General advantages	Earlier sampling	Often provides more DNA and may better reflect current laboratory standards
General concerns	Removing 1 of few cells may be more disruptive	Requires embryo to reach blastocyst stage

Day 5 biopsy is generally considered the current standard in many IVF centers because it allows sampling of more cells and may be less disruptive to the embryo than removing one cell from a smaller day 3 embryo. Even so, clinic experience and lab quality remain major factors.

What's normal vs what's not?

People often search for a “normal embryo biopsy result,” but the language can be confusing. Genetic testing results are usually reported using terms such as euploid, aneuploid, mosaic, affected, unaffected, or carrier.

How embryo biopsy results are commonly interpreted

Euploid: The embryo appears to have the expected number of chromosomes.
Aneuploid: The embryo appears to have extra or missing chromosomes.
Mosaic: The sample suggests a mixture of cells, some with normal chromosome content and some with abnormalities.
Unaffected: In PGT-M, the embryo does not appear to carry the disease-causing genotype being tested.
Carrier: In some recessive conditions, the embryo carries one copy of a mutation but is not expected to be affected.
Affected: The embryo appears to have the genetic change that causes the inherited condition being tested.
No result or inconclusive: The sample did not produce a clear answer.

“Normal” depends on what was tested. A euploid result on PGT-A means chromosome number looks normal, but it does not rule out all genetic disease, birth defects, developmental conditions, or pregnancy complications. The MedlinePlus overview of preimplantation genetic testing explains that PGT can reduce certain risks but cannot provide complete certainty.

What do abnormal or unexpected results mean?

An abnormal result may mean:

The embryo is less likely to implant successfully
The embryo may carry a high risk of miscarriage
The embryo may be affected by the known condition being tested
Further counseling is needed because the result is mosaic or inconclusive

Mosaic results deserve special attention. Mosaic embryos can sometimes still lead to healthy live births, but they require careful review with a fertility specialist and often a genetic counselor. The interpretation of mosaicism is nuanced, and management varies by clinic and case.

Benefits, limitations, and risks

Potential benefits

May help avoid transferring embryos with known serious genetic conditions
May improve embryo selection in certain patients
Can be especially valuable for couples with known inherited disorders or structural chromosome rearrangements
May reduce the likelihood of transferring clearly aneuploid embryos
Can provide additional information after recurrent pregnancy loss or previous IVF failures, depending on the case

Limitations

The sampled cells may not perfectly represent the entire embryo
Mosaicism can make results harder to interpret
Testing does not assess every possible disease or future health issue
Not all patients clearly benefit from PGT-A
There can be false positive, false negative, and no-call results
Biopsy adds cost, time, and complexity to IVF

Risks

Possible damage to the embryo during biopsy
Possible loss of embryos during freezing or thawing
Potential emotional stress from ambiguous or disappointing results
Risk of overinterpreting a result as more certain than it really is

The ASRM guidance on PGT-A and the ESHRE PGT guideline resources both stress that embryo biopsy and genetic testing should be interpreted in context rather than treated as a guarantee.

Male factor infertility and sperm quality

Many couples wonder whether embryo biopsy is recommended because of poor sperm quality. The answer is: sometimes, but not automatically.

Severe male factor infertility can affect fertilization rates, embryo development, and potentially chromosomal stability. Some studies have explored links between sperm DNA fragmentation and poorer reproductive outcomes, but clinical decisions still depend on the broader picture rather than one sperm metric alone. If a man has a known genetic disorder, a balanced translocation, or a strong family history of inherited disease, embryo biopsy with targeted testing may be particularly relevant.

On the other hand, if the issue is low sperm count, low motility, or morphology alone, the first step is still a proper male infertility workup. That may include:

Semen analysis
Repeat semen testing if results are abnormal
Hormone testing such as testosterone, FSH, and LH when indicated
Scrotal exam or ultrasound in selected cases
Genetic tests such as karyotype or Y chromosome microdeletion testing for severe sperm abnormalities
Evaluation for varicocele, infection, obstruction, medications, heat exposure, or lifestyle factors

If you are a man considering IVF with embryo biopsy, it helps to ask two separate questions:

What is causing the fertility problem?
Is there a specific genetic reason to biopsy embryos, or are we using it mainly for embryo selection?

Those are not the same question, and the answer can change the value of testing.

Who might consider embryo biopsy?

Embryo biopsy is not necessary for every IVF cycle. It may be considered in situations such as:

A known inherited single-gene disorder in one or both genetic parents
A parental balanced translocation or other structural chromosome rearrangement
Recurrent pregnancy loss, especially when chromosomal causes are suspected
Some cases of advanced maternal age
Repeated unsuccessful IVF cycles, depending on clinical judgment
Use of IVF specifically to reduce the chance of passing on a genetic condition

It may be less helpful when:

There is no known genetic risk and the patient population is unlikely to benefit meaningfully
Very few embryos are expected, making the extra step less useful in practice
The emotional or financial burden outweighs the likely benefit

The decision is highly personal. A reproductive endocrinologist, embryology lab, and genetic counselor can help weigh the tradeoffs.

When to talk to a fertility specialist

You should consider speaking with a fertility specialist or reproductive urologist if:

You or your partner has a known inherited genetic condition
You have had multiple miscarriages
You have had failed IVF cycles and want to understand whether genetic testing may help
You have severe male factor infertility or abnormal semen analyses
You have a personal or family history of chromosomal rearrangements
You are considering IVF and want to understand whether PGT is worth it in your situation

If there is a known genetic issue, ask for genetic counseling before treatment. That step can clarify what testing can and cannot tell you, what the limitations are, and how results may affect embryo transfer decisions.

Questions to ask your doctor

Why are you recommending embryo biopsy in our case?
Are you suggesting PGT-A, PGT-M, or PGT-SR?
How often does your clinic perform blastocyst biopsy, and what are your lab outcomes?
What are the chances of getting no-result or mosaic embryos?
Will all embryos be frozen after biopsy?
How should we interpret mosaic findings if they come back?
Could male factor infertility or a sperm-related genetic issue be part of the reason we are considering this?
What are the costs, timelines, and possible downsides?
Will we meet with a genetic counselor before making decisions?
If we do not use embryo biopsy, what are our alternatives?

IVF: In vitro fertilization, the broader treatment process in which embryo biopsy is performed.
ICSI: Intracytoplasmic sperm injection, often used during IVF when PGT is planned.
Blastocyst: A more developed embryo stage, usually reached around day 5.
Trophectoderm biopsy: Another name for blastocyst-stage embryo biopsy.
Euploid: An embryo with the expected chromosome number.
Aneuploid: An embryo with extra or missing chromosomes.
Mosaic embryo: An embryo with a mix of cell lines showing different chromosome patterns.
Karyotype: A chromosome test sometimes used in adults with infertility or recurrent miscarriage.
Carrier screening: Testing adults for inherited disease risk before or during fertility treatment.
Semen analysis: The basic test used to assess sperm count, motility, and morphology.

Frequently asked questions

Is embryo biopsy the same as PGT?

Not exactly. Embryo biopsy is the step where cells are removed from the embryo. PGT is the genetic testing performed on those cells.

Can embryo biopsy harm the embryo?

It can, although modern blastocyst biopsy is designed to minimize risk. Experienced labs generally perform it safely, but it is not risk-free.

Does embryo biopsy improve IVF success rates?

Sometimes, in selected patients. It may help identify embryos more likely to be suitable for transfer, but it does not guarantee pregnancy or live birth and may not benefit every IVF patient equally.

What is a mosaic embryo?

A mosaic embryo has a mix of cells with different chromosome findings. Some mosaic embryos can still result in healthy births, but interpretation is complex and needs specialist counseling.

Is embryo biopsy recommended for male infertility?

Not automatically. It may be relevant if there is a known genetic issue, recurrent loss, or another specific reason. Poor semen parameters alone do not always mean biopsy is necessary.

How many cells are removed during embryo biopsy?

In modern blastocyst biopsy, a few trophectoderm cells are typically removed. The exact number varies by lab technique.

Can embryo biopsy detect all genetic problems?

No. It can only assess what the chosen test is designed to analyze. A euploid or unaffected result does not rule out every disease, birth defect, or future health issue.

Do embryos need to be frozen after biopsy?

Often yes. Many clinics freeze embryos after biopsy while waiting for results, then plan a frozen embryo transfer later.

Is embryo biopsy accurate?

It is useful but not perfect. Accuracy depends on the testing method, the quality of the sample, the lab, and biological factors such as mosaicism.

Should we still do prenatal testing after PGT?

In many cases, yes. PGT does not replace standard prenatal care or all prenatal genetic screening and diagnostic options. Your obstetric team can explain what is recommended in pregnancy.